Alcohol

Alcohol

SCHEMBL142048

CCO.Oc1ccccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.66
SLC6A4 P31645 2/20 0.66
ABCB11 O95342 1/20 0.66
CHRM2 P08172 1/20 0.66
HTR1A P08908 1/20 0.66
ADRA2A P08913 1/20 0.66
CHRM1 P11229 1/20 0.66
ADRA2B P18089 1/20 0.66
ADRA2C P18825 1/20 0.66
DRD1 P21728 1/20 0.66
DRD4 P21917 1/20 0.66
ACHE P22303 1/20 0.66
SLC6A2 P23975 1/20 0.66
HTR2A P28223 1/20 0.66
HTR2C P28335 1/20 0.66
CCKBR P32239 1/20 0.66
ADRA1A P35348 1/20 0.66
HRH1 P35367 1/20 0.66
OPRM1 P35372 1/20 0.66
DRD3 P35462 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL142049 0.96 ABCB11 (0.66) DRD2SLC6A4ABCB11CHRM2HTR1A
Methane SCHEMBL7348385 0.96 HTR1A (0.65) DRD2SLC6A4ABCB11CHRM2HTR1A
SCHEMBL5993554 0.93 HTR1A (0.62) DRD2SLC6A4ABCB11CHRM2HTR1A
Methyl Alcohol SCHEMBL718326 0.90 DRD2 (0.69) DRD2SLC6A4ABCB11CHRM2HTR1A
SCHEMBL9101152 0.89 HTR1A (0.68) DRD2SLC6A4ABCB11CHRM2HTR1A
Methyl Alcohol SCHEMBL929693 0.88 CHRM2 (0.65) DRD2SLC6A4ABCB11CHRM2HTR1A
Methyl Alcohol SCHEMBL929694 0.88 ABCB11 (0.66) DRD2SLC6A4ABCB11CHRM2HTR1A
Methyl Alcohol SCHEMBL718327 0.87 HTR1A (0.76) DRD2SLC6A4ABCB11CHRM2HTR1A
SCHEMBL5995122 0.87 HTR1A (0.67) DRD2HTR1AHTR2A
Hydrochloric Acid SCHEMBL1545933 0.86 HTR1A (0.66) DRD2HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458507-B1 Antipsychotic treatment based on SNP genotype VANDA PHARMACEUTICALS, INC. (US) 2016-10-04 US claimed
US-20160265060-A1 ANTIPSYCHOTIC TREATMENT BASED ON SNP GENOTYPE VANDA PHARMACEUTICALS, INC. 2016-09-15 US claimed
US-9328387-B2 Antipsychotic treatment based on SNP genotype VANDA PHARMACEUTICALS, INC. (US) 2016-05-03 US claimed
US-20100292211-A1 ANTIPSYCHOTIC TREATMENT BASED ON SNP GENOTYPE VANDA PHARMACEUTICALS, INC. 2010-11-18 US claimed
US-20100249188-A1 PREDICTION OF QT PROLONGATION BASED ON SNP GENOTYPE VANDA PHARMACEUTICALS, INC. 2010-09-30 US claimed
EP-2198048-A2 PREDICTION OF QT PROLONGATION BASED ON SNP GENOTYPE Vanda Pharmaceuticals Inc. (US) 2010-06-23 EP claimed
EP-2198049-A1 ANTIPSYCHOTIC TREATMENT BASED ON SNP GENOTYPE Vanda Pharmaceuticals Inc. (US) 2010-06-23 EP claimed
WO-2009036100-A2 PREDICTION OF QT PROLONGATION BASED ON SNP GENOTYPE VANDA PHARMACEUTICALS, INC. (US) 2009-03-19 WO claimed
WO-2009036056-A1 ANTIPSYCHOTIC TREATMENT BASED ON SNP GENOTYPE VANDA PHARMACEUTICALS, INC. (US) 2009-03-19 WO claimed
US-RE39198-E1 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics AVENTIS PHARMACEUTICALS INC. (US) 2006-07-18 US claimed
US-5364866-A Side effect reduction HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1994-11-15 US claimed
EP-0612318-A1 HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1994-08-31 EP claimed
EP-0542136-A1 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1993-05-19 EP claimed
WO-1993009102-A1 HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1993-05-13 WO claimed
US-20230190727-A1 METHOD OF TREATMENT OF SCHIZOPHRENIA VANDA PHARMACEUTICALS INC. 2023-06-22 US disclosed
US-11607408-B2 Method of treatment of schizophrenia VANDA PHARMACEUTICALS INC. (US) 2023-03-21 US disclosed
US-11214827-B2 Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone VANDA PHARMACEUTICALS INC. (US) 2022-01-04 US disclosed
EP-0612318-A1 HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1994-08-31 EP disclosed
EP-0542136-A1 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1993-05-19 EP disclosed
WO-1993009102-A1 HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1993-05-13 WO disclosed